Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.
about
Frequency of flutamide induced hepatotoxicity in patients with prostate carcinomaTAMH: A Useful In Vitro Model for Assessing Hepatotoxic MechanismsComparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase.Hirsutes. II: Treatment.Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial.Anti-androgens for the treatment of hirsutism.Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening.Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women.Morphological and enzymatic changes caused by a long-term treatment of female rats with a low dose of gonadoliberin agonist and antagonistHepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.Flutamide attenuates pro-inflammatory cytokine production and hepatic injury following trauma-hemorrhage via estrogen receptor-related pathway.The antiandrogen flutamide is a novel aryl hydrocarbon receptor ligand that disrupts bile acid homeostasis in mice through induction of Abcc4Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women.Investigating the application of a nitroreductase-expressing transgenic zebrafish line for high-throughput toxicity testing.Antiandrogen therapy in dermatology.Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF).Flutamide-induced cytotoxicity and oxidative stress in an in vitro rat hepatocyte system.Mechanistic study on liver tumor promoting effects of flutamide in rats.Hepatotoxicity during low-dose flutamide treatment for hirsutism.Spironolactone-induced hepatitis.Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: a preliminary study.Optimization of formulation parameters for the preparation of flutamide liposomes by 3(3) factorial 26-term logit model.Induction of liver cytochrome P450 1A2 expression by flutamide in rats.The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p.Treatment of hyperandrogenism in womenManaging hirsutism in gynaecological practiceZone analysis by two-dimensional electrophoresis with accelerator mass spectrometry of in vivo protein bindings of idiosyncratic hepatotoxicants troglitazone and flutamide bioactivated in chimeric mice with humanized liver
P2860
Q28373914-C66AE724-4DA9-4D18-B684-760396030528Q28818435-D36C97B2-4ABE-4A33-999C-8D9F189FA0EBQ30010969-711C94F3-D964-49DB-9E45-084351491565Q32021686-9D3B8B21-F8C1-4BBC-B26F-97F225B1678FQ34388347-5C09354B-D057-4C8A-B146-58B7780774ADQ34544658-9AB42911-4F9D-4011-A6B2-6644393CC41DQ34663837-AA28609B-C0C3-49BE-AD43-CC82D24FEF66Q36366167-5D63D775-87C8-4C6F-A546-BC929F9AE3A9Q36577239-7683FB85-13F7-4D8C-98CD-0A7F01694030Q37724173-DB4C3599-14B9-4388-AA8E-83E5AB0D30B0Q38305485-BFC4982D-E76D-45E9-80C9-B452E8FB9D8FQ38749517-EC490488-CD80-4AE4-9A95-9CAEA5C9557CQ40433879-968A585E-62F9-4CB6-B2FD-3DC3E00DA50DQ41130777-EE6EEE16-97DE-4AEB-B58E-EF6C0DC78175Q41208689-81E3A970-5414-459C-ABAE-4C9E07BD1583Q42463314-D1DED9A0-7D83-465F-801A-72350430B987Q42703698-A7CB6313-0A14-4237-B57E-640DF13768ECQ42723928-4B8FFFA6-D098-439F-9ED7-4279A711B4FDQ43244963-AE600DD2-6412-4575-A452-CA9CF8ED60D7Q43697926-48018B91-FA0F-46F2-9BA0-3E5B25A617D8Q43969598-591278DE-2577-4DE9-B9A1-E4BF86ACF98FQ45174652-491C0AA5-2385-43B3-BE36-21C14D518A09Q46753491-233121BC-DB0A-4439-8D8F-3E212483D3B2Q47116057-91D55740-E41C-477B-AB5A-C96080331859Q55892518-9CADBB91-1510-45DC-98D3-7C48508D03B2Q56429442-7B03D07C-AF68-4D56-ABBB-9667FBE04AE0Q59153006-4EE7EC80-43EE-4347-922D-115714C2C795
P2860
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Incidence of liver toxicity as ...... e in prostate cancer patients.
@en
Incidence of liver toxicity as ...... e in prostate cancer patients.
@nl
type
label
Incidence of liver toxicity as ...... e in prostate cancer patients.
@en
Incidence of liver toxicity as ...... e in prostate cancer patients.
@nl
prefLabel
Incidence of liver toxicity as ...... e in prostate cancer patients.
@en
Incidence of liver toxicity as ...... e in prostate cancer patients.
@nl
P2093
P1476
Incidence of liver toxicity as ...... e in prostate cancer patients.
@en
P2093
M Tremblay
P304
P356
10.1016/0002-9343(92)90741-S
P407
P577
1992-05-01T00:00:00Z